Balchem Co. (NASDAQ:BCPC – Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 492,400 shares, a growth of 12.8% from the November 30th total of 436,600 shares. Approximately 1.5% of the company’s stock are short sold. Based on an average daily trading volume, of 125,700 shares, the days-to-cover ratio is currently 3.9 days.
Balchem Stock Performance
Shares of BCPC traded down $0.98 during midday trading on Wednesday, reaching $162.99. The stock had a trading volume of 88,236 shares, compared to its average volume of 112,037. The company has a current ratio of 2.98, a quick ratio of 1.90 and a debt-to-equity ratio of 0.21. The firm has a 50 day simple moving average of $174.24 and a 200-day simple moving average of $170.48. The firm has a market cap of $5.30 billion, a PE ratio of 43.81, a P/E/G ratio of 5.32 and a beta of 0.67. Balchem has a one year low of $135.84 and a one year high of $186.03.
Balchem Increases Dividend
The firm also recently declared an annual dividend, which will be paid on Friday, January 17th. Shareholders of record on Thursday, December 26th will be given a dividend of $0.87 per share. This represents a yield of 0.4%. The ex-dividend date is Thursday, December 26th. This is an increase from Balchem’s previous annual dividend of $0.79. Balchem’s payout ratio is 23.39%.
Institutional Trading of Balchem
Analyst Ratings Changes
Several equities analysts have recently weighed in on the company. HC Wainwright raised their price objective on Balchem from $185.00 to $190.00 and gave the company a “buy” rating in a report on Monday, November 4th. StockNews.com raised Balchem from a “hold” rating to a “buy” rating in a research report on Monday, October 28th.
Get Our Latest Research Report on BCPC
Balchem Company Profile
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
See Also
- Five stocks we like better than Balchem
- Investing in Commodities: What Are They? How to Invest in Them
- Work and Play: Investing in the Rise of Bleisure Travel
- What is the Australian Securities Exchange (ASX)
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- How to Start Investing in Real Estate
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.